The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels

[1]  F. Saad,et al.  Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer , 2018, The New England journal of medicine.

[2]  H. Scher,et al.  Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[4]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[5]  F. Saad,et al.  Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. , 2017 .

[6]  E. Antonarakis,et al.  Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort , 2016, European urology.

[7]  I. Thompson,et al.  Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. , 2016, JAMA oncology.

[8]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[9]  D. Beyersdorff,et al.  Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management , 2016, World Journal of Urology.

[10]  E. Crawford,et al.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. , 2015, The Journal of urology.

[11]  F. Saad,et al.  Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. , 2015, European urology.

[12]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[13]  P. Troncoso,et al.  Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). , 2014 .

[14]  B. Tombal,et al.  Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. , 2014, The Lancet. Oncology.

[15]  D. Galvão,et al.  Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer , 2014, Journal of medical imaging and radiation oncology.

[16]  S. Larson,et al.  Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Pusztai,et al.  Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Scher,et al.  ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[20]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[21]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[22]  A. E. Friedman.  Re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56:594-605. , 2010, European urology.

[23]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. , 2009, European urology.

[24]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[26]  B. Haynes,et al.  Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase) , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  M. Dowsett,et al.  Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). , 1994, The Journal of steroid biochemistry and molecular biology.